Circulating miR-375 and miR-199a-3p as potential biomarkers for the diagnosis of hepatocellular carcinoma

Tumor Biology

Volumn 36, Issue 6, 2015, Pages 4501-4507

  Yin, Jian ^a   Hou, Peng ^a   Wu, Zhiqiang ^a   Wang, Tao ^a   Nie, Yanxiao ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Biomarker; Hepatocellular carcinoma (HCC); miR 199a 3p; miR 375

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 199A 3P; MICRORNA 375; UNCLASSIFIED DRUG; MIRN199 MICRORNA, HUMAN; MIRN375 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; BLOOD SAMPLING; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; DISEASE MARKER; DRINKING BEHAVIOR; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MUTATION; PREDICTIVE VALUE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; SENSITIVITY AND SPECIFICITY; SMOKING HABIT; TUMOR VOLUME; AGED; BIOSYNTHESIS; BLOOD; GENE EXPRESSION REGULATION; LIVER TUMOR; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING; TUMOR MARKERS, BIOLOGICAL;

EID: 84938995474     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3092-0     Document Type: Article

References (54)

1. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127:S5–S16.
2. Song P, Gao J, Inagaki Y, Kokudo N, Hasegawa K, et al. Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and china. Liver Cancer. 2013;2:31–9.
3. Asia-Pacific Working Party on Prevention of Hepatocellular C Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements. J Gastroenterol Hepatol 2010:25:657-663.
4. Yuen MF, Hou JL, Chutaputti A, Asia Pacific Working Party on Prevention of Hepatocellular Carcinoma. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol. 2009;24:346–53.
5. Hu B, Tian X, Sun J, Meng X. Evaluation of individual and combined applications of serum biomarkers for diagnosis of hepatocellular carcinoma: a meta-analysis. Int J Mol Sci. 2013;14:23559–80.
6. Harada N, Hiramatsu N, Oze T, Morishita N, Yamada R, et al. Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin. J Viral Hepat. 2014;21:357–65.
7. Bao YX, Cao Q, Yang Y, Mao R, Xiao L, et al. Expression and prognostic significance of golgiglycoprotein73 (GP73) with epithelial-mesenchymal transition (EMT) related molecules in hepatocellular carcinoma (HCC). Diagn Pathol. 2013;8:197.
8. Zhu K, Dai Z, Zhou J. Biomarkers for hepatocellular carcinoma: progression in early diagnosis, prognosis, and personalized therapy. Biomarker Res. 2013;1:10.
9. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–2.
10. Han LL, Nan HC, Tian T, Guo H, Hu TH, et al. Expression and significance of the novel tumor-suppressor gene SMG-1 in hepatocellular carcinoma. Oncol Rep. 2014;31:2569–78.
11. Chen MH, Jan YH, Chang PM, Chuang YJ, Yeh YC, et al. Expression of GOLM1 correlates with prognosis in human hepatocellular carcinoma. Ann Surg Oncol. 2013;20 Suppl 3:S616–624.
12. Zhang Y, Zhang JX, Huang LL, He LJ, Liao YJ, et al. Low expression of BARX2 in human primary hepatocellular carcinoma correlates with metastasis and predicts poor prognosis. Hepatol Res: Off J Japan Soc Hepatol. 2014.
13. Bostjancic E, Zidar N, Glavac D. MicroRNA microarray expression profiling in human myocardial infarction. Dis Markers. 2009;27:255–68.
14. Leivonen SK, Makela R, Ostling P, Kohonen P, Haapa-Paananen S, et al. Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines. Oncogene. 2009;28:3926–36.
15. Cho W, Ziogas DE, Katsios C, Roukos DH. Emerging personalized oncology: sequencing and systems strategies. Future Oncol. 2012;8:637–41.
16. Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet. 2010;11:685–96.
17. Kumar V, Kato N, Urabe Y, Takahashi A, Muroyama R, et al. Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet. 2011;43:455–8.
18. Krawczyk M, Mullenbach R, Weber SN, Zimmer V, Lammert F. Genome-wide association studies and genetic risk assessment of liver diseases. Nat Rev Gastroenterol Hepatol. 2010;7:669–81.
19. Bai DS, Dai Z, Zhou J, Liu YK, Qiu SJ, et al. Capn4 overexpression underlies tumor invasion and metastasis after liver transplantation for hepatocellular carcinoma. Hepatology. 2009;49:460–70.
20. Dai Z, Zhou J, Qiu SJ, Liu YK, Fan J. Lectin-based glycoproteomics to explore and analyze hepatocellular carcinoma-related glycoprotein markers. Electrophoresis. 2009;30:2957–66.
21. Varnholt H, Drebber U, Schulze F, Wedemeyer I, Schirmacher P, et al. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology. 2008;47:1223–32.
22. Budhu A, Ji J, Wang XW. The clinical potential of microRNAs. J Hematol Oncol. 2010;3:37.
23. Zhao J, Lu Q, Zhu J, Fu J, Chen YX. Prognostic value of miR-96 in patients with acute myeloid leukemia. Diagn Pathol. 2014;9:76.
24. Liu F, Xiong Y, Zhao Y, Tao L, Zhang Z, et al. Identification of aberrant microRNA expression pattern in pediatric gliomas by microarray. Diagn Pathol. 2013;8:158.
25. Wang W, Li F, Zhang Y, Tu Y, Yang Q, et al. Reduced expression of miR-22 in gastric cancer is related to clinicopathologic characteristics or patient prognosis. Diagn Pathol. 2013;8:102.
26. Giray BG, Emekdas G, Tezcan S, Ulger M, Serin MS, et al. Profiles of serum microRNAs; miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma. Mol Biol Rep. 2014;41:4513–9.
27. Qi J, Wang J, Katayama H, Sen S, Liu SM. Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma. Neoplasma. 2013;60:135–42.
28. Luo J, Chen M, Huang H, Yuan T, Zhang M, et al. Circulating microRNA-122a as a diagnostic marker for hepatocellular carcinoma. OncoTargets Ther. 2013;6:577–83.
29. Liu AM, Yao TJ, Wang W, Wong KF, Lee NP, et al. Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open. 2012;2:e000825.
30. Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. Jama. 2007;297:1901–8.
31. Minna E, Romeo P, De Cecco L, Dugo M, Cassinelli G, et al. miR-199a-3p displays tumor suppressor functions in papillary thyroid carcinoma. Oncotarget. 2014;5:2513–28.
32. Wan D, He S, Xie B, Xu G, Gu W, et al. Aberrant expression of miR-199a-3p and its clinical significance in colorectal cancers. Med Oncol. 2013;30:378.
33. Naugler WE, Schwartz JM. Hepatocellular carcinoma. Dis-a-Month: DM. 2008;54:432–44.
34. Sanyal AJ, Yoon SK, Lencioni R. The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist. 2010;15 Suppl 4:14–22.
35. Trinchet JC, Chaffaut C, Bourcier V, Degos F, Henrion J, et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology. 2011;54:1987–97.
36. Aghoram R, Cai P, Dickinson JA. Alpha-foetoprotein and/or liver ultrasonography for screening of hepatocellular carcinoma in patients with chronic hepatitis B. Cochrane Database Syst Rev. 2012;9, CD002799.
37. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Gen. 2004;5:522–31.
38. Geng Q, Fan T, Zhang B, Wang W, Xu Y, et al. Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer. Respir Res. 2014;15:149.
39. Poy MN, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X, et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature. 2004;432:226–30.
40. Zhou J, Song S, He S, Zhu X, Zhang Y, et al. MicroRNA-375 targets PDK1 in pancreatic carcinoma and suppresses cell growth through the Akt signaling pathway. Int J Mol Med. 2014;33:950–6.
41. He XX, Chang Y, Meng FY, Wang MY, Xie QH, et al. MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. Oncogene. 2012;31:3357–69.
42. Ding L, Xu Y, Zhang W, Deng Y, Si M, et al. MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. Cell Res. 2010;20:784–93.
43. Mathe EA, Nguyen GH, Bowman ED, Zhao Y, Budhu A, et al. MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res: Off J Am Assoc Cancer Res. 2009;15:6192–200.
44. de Souza Rocha Simonini P, Breiling A, Gupta N, Malekpour M, Youns M, et al. Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor alpha in breast cancer cells. Cancer Res. 2010;70:9175–84.
45. Yu H, Jiang L, Sun C, Li Guo L, Lin M, et al. Decreased circulating miR-375: a potential biomarker for patients with non-small-cell lung cancer. Gene. 2014;534:60–5.
46. Shao Y, Geng Y, Gu W, Huang J, Ning Z, et al. Prognostic significance of microRNA-375 downregulation in solid tumors: a meta-analysis. Dis Markers. 2014;2014:626185.
47. Wu C, Li M, Hu C, Duan H. Clinical significance of serum miR-223, miR-25 and miR-375 in patients with esophageal squamous cell carcinoma. Mol Biol Rep. 2014;41:1257–66.
48. Chang C, Shi H, Wang C, Wang J, Geng N, et al. Correlation of microRNA-375 downregulation with unfavorable clinical outcome of patients with glioma. Neurosci Lett. 2012;531:204–8.
49. Li J, Li X, Li Y, Yang H, Wang L, et al. Cell-specific detection of miR-375 downregulation for predicting the prognosis of esophageal squamous cell carcinoma by miRNA in situ hybridization. PLoS One. 2013;8:e53582.
50. Kong KL, Kwong DL, Chan TH, Law SY, Chen L, et al. MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut. 2012;61:33–42.
51. Hu A, Huang JJ, Xu WH, Jin XJ, Li JP, et al. miR-21 and miR-375 microRNAs as candidate diagnostic biomarkers in squamous cell carcinoma of the larynx: association with patient survival. Am J Transl Res. 2014;6:604–13.
52. Jiang J, Gusev Y, Aderca I, Mettler TA, Nagorney DM, et al. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res: Off J Am Assoc Cancer Res. 2008;14:419–27.
53. Ichimi T, Enokida H, Okuno Y, Kunimoto R, Chiyomaru T, et al. Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer. 2009;125:345–52.
54. Fornari F, Milazzo M, Chieco P, Negrini M, Calin GA, et al. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 2010;70:5184–93.